Entero Therapeutics, Inc. (GRDX) — S-1 Filings
All S-1 filings from Entero Therapeutics, Inc.. Browse 2 IPO Filing reports with AI-powered summaries and risk analysis.
S-1 Filings (2)
-
Entero Therapeutics Narrows Focus to Adrulipase Amidst Merger Rescission, Cash Crunch
— Aug 26, 2025 Risk: high
Entero Therapeutics, Inc. (GRDX) is undergoing a significant strategic shift, discontinuing its Latiglutenase, Capeserod, and Niclosamide programs to focus sole -
Entero Therapeutics Files S-1 for Public Offering
— May 12, 2025 Risk: medium
Entero Therapeutics, Inc. filed an S-1 registration statement on May 12, 2025, to register securities for public offering. The company, formerly known as First
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX